Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Julie Hyman hosts the 3-5 p.m. ET show on Yahoo Finance Live. Julie has been a financial journalist for more than 20 years, covering events including the Great Financial Crisis, the collapse of ...

Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company said it had a loss of 78 cents per share. The ...

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are currently covering the firm ...

NASDAQ CRBP opened at $6.79 on Thursday. Corbus Pharmaceuticals has a 12 month low of $6.54 and a 12 month high of $61.90. The stock’s fifty day moving average price is $9.98 and its 200-day ...

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...

In our poll earlier this week, Yahoo News UK asked readers: "How worried are you about the Ukraine war escalating?" It received 5,827 votes and showed 71% of Yahoo readers are very worried, compared ...

Investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 17, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...